GulbranGråstein
20.09.2024 kl 10:56
5496
Om
David Colpman joined Shire in 1999 and was instrumental in delivering the M&A and licensing strategy key to Shire's success and eventual $45Bn Valuation. David reported to the CEO as Head of Business Development and managed a team of 25, between 2012 and 2014 David and his team acquired six companies and completed about 30 other deals. Notable transactions included the $4.2bn acquisition of ViroPharma, together with acquisitions of Sarcode (Xiidra for dry eye), Lumena and Fibrotech.
Earlier in his career at Shire he identified the opportunity for Shire to expand into Rare Diseases and identified and led the acquisition of TKT which went on to become the cornerstone of Shire's successful rare disease business. He also in-licensed Lialda, which became the sector leader in treating Ulcerative Colitis.
Since 2014 David has offered strategic BD advice to Biotech and Pharma companies completing a series of landmark deals with total potential value of around $5.5bn. Notable transactions include:
* led the out-licensing of Alligator AB’s immuno-oncology agent, ADC 103, to Johnson and Johnson, securing a $700m collaboration (at the time the biggest such deal in Swedish Biotech)
* acted as sole adviser on the sale of Cormorant AB to BMS in a potential $520m deal including $95M in upfront and near term payments for an IL8 antagonist in Phase I.
* key to the sale of Agalimmune Ltd to Bioline Rx
* established a research and option agreement with J&J, for Diaprost's prostate cancer treatment .
* led the sale of Ziylo, with its very early stage glucose binding molecules, to Novo Nordisk in a deal that could exceed $800M in value.
* out licensed a second early stage Diaprost prostate cancer asset to RadioPharm Theranostics in a deal worth up to $125M
* as a Board Member actively participated in the sale of Forendo Oy to Organon Inc for a potential total consideration of $954m
* as a Board member supported the sale of HRA Pharma to Perrigo for $2.1M
* Appointed as an Independent Board member of the NASDAQ listed HighCape SPAC which June 2021 completed a merger with Quantum SI
* as a Non Exec Director supported the License of Oak Hill Bio's neonatology project to Chiesi in 2023
David has advised numerous US and European Biotech and Speciality companies in their BD strategies and has and continues to serve on a number of Boards in the Life Sciences field .
David is a pharmacist by training and prior to joining Shire in 1999 headed Licensing and Alliances at Novo Nordisk in Denmark and spent two years in BD at Glaxo Wellcome UK.
David Colpman joined Shire in 1999 and was instrumental in delivering the M&A and licensing strategy key to Shire's success and eventual $45Bn Valuation. David reported to the CEO as Head of Business Development and managed a team of 25, between 2012 and 2014 David and his team acquired six companies and completed about 30 other deals. Notable transactions included the $4.2bn acquisition of ViroPharma, together with acquisitions of Sarcode (Xiidra for dry eye), Lumena and Fibrotech.
Earlier in his career at Shire he identified the opportunity for Shire to expand into Rare Diseases and identified and led the acquisition of TKT which went on to become the cornerstone of Shire's successful rare disease business. He also in-licensed Lialda, which became the sector leader in treating Ulcerative Colitis.
Since 2014 David has offered strategic BD advice to Biotech and Pharma companies completing a series of landmark deals with total potential value of around $5.5bn. Notable transactions include:
* led the out-licensing of Alligator AB’s immuno-oncology agent, ADC 103, to Johnson and Johnson, securing a $700m collaboration (at the time the biggest such deal in Swedish Biotech)
* acted as sole adviser on the sale of Cormorant AB to BMS in a potential $520m deal including $95M in upfront and near term payments for an IL8 antagonist in Phase I.
* key to the sale of Agalimmune Ltd to Bioline Rx
* established a research and option agreement with J&J, for Diaprost's prostate cancer treatment .
* led the sale of Ziylo, with its very early stage glucose binding molecules, to Novo Nordisk in a deal that could exceed $800M in value.
* out licensed a second early stage Diaprost prostate cancer asset to RadioPharm Theranostics in a deal worth up to $125M
* as a Board Member actively participated in the sale of Forendo Oy to Organon Inc for a potential total consideration of $954m
* as a Board member supported the sale of HRA Pharma to Perrigo for $2.1M
* Appointed as an Independent Board member of the NASDAQ listed HighCape SPAC which June 2021 completed a merger with Quantum SI
* as a Non Exec Director supported the License of Oak Hill Bio's neonatology project to Chiesi in 2023
David has advised numerous US and European Biotech and Speciality companies in their BD strategies and has and continues to serve on a number of Boards in the Life Sciences field .
David is a pharmacist by training and prior to joining Shire in 1999 headed Licensing and Alliances at Novo Nordisk in Denmark and spent two years in BD at Glaxo Wellcome UK.